DUBLIN--(BUSINESS WIRE)--The "Caspase 8 - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Caspase-8 is a caspase protein, encoded by the CASP8 gene. It binds to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation.
- The report provides a snapshot of the global therapeutic landscape for Caspase 8
- The report reviews Caspase 8 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Caspase 8 targeted therapeutics and enlists all their major and minor projects
- The report assesses Caspase 8 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
-
The report reviews latest news and deals related to Caspase 8
targeted therapeutics
Companies Featured
- BeyondSpring Pharmaceuticals Inc.
- Conatus Pharmaceuticals Inc.
- Novartis AG
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/trxpg3/caspase_8?w=4
